Stevenage Bioscience Catalyst launches accelerator programme for biotech start-ups

Stevenage Bioscience Catalyst (SBC) offices

Stevenage Bioscience Catalyst (SBC) has launched a free accelerator programme to give data-focused biotech start-ups the skills they need to get potential new drugs and therapies to market more quickly.

The programme will run from May and is aimed at supporting start-up companies working to discover new drugs. Those selected will take part in an 18-week programme during which they will have the opportunity to network and learn from experts in the pharmaceutical and biotech industries. Start-ups will be able to build their expertise in structuring deals, accessing data, intellectual property and attract funding. At the end of the programme, founders will have the chance to pitch their idea in front of leading investors and pharmaceutical experts.

Dr Sally Ann Forsyth OBE, CEO at SBC, said, “At Stevenage Bioscience Catalyst, as a not-for-profit organisation, we are committed to enabling life science companies to connect, grow and succeed at every stage of their development. We are absolutely delighted to launch this programme which will help start-ups build their expertise, supporting them to establish the funding and relationships they need to move to the next level.”

To read more information, click here.

Stevenage Bioscience Catalyst is a leading location for development and commercialisation of advanced therapeutics. The Campus is home to GSK, the Cell & Gene Therapy Manufacturing Catapult, LifeArc and Cytiva plus 40+ start-up companies which together have raised £1.8 bn equity investment, IPO/FPO, grants and acquisitions since 2012. The facilities provide business support, scientific equipment and scale up advice.

Stevenage Bioscience Catalyst